Comparative Pharmacology
Head-to-head clinical analysis: BRIVARACETAM versus CENOBAMATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIVARACETAM versus CENOBAMATE.
BRIVARACETAM vs CENOBAMATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brivaracetam is a high-affinity synaptic vesicle glycoprotein 2A (SV2A) ligand, binding to SV2A with 15- to 30-fold higher affinity than levetiracetam. It modulates neurotransmitter release, reducing neuronal excitability. It also inhibits voltage-gated sodium channels at clinically relevant concentrations.
Cenobamate is a tetrazole-derived anticonvulsant that modulates GABA A receptors, preferentially inhibiting the persistent sodium current and activating potassium currents (M-current). It also enhances GABA-mediated inhibition and reduces excitatory neurotransmitter release.
50 mg orally twice daily, with or without food. May increase to 100 mg twice daily based on tolerability and efficacy. Maximum 200 mg twice daily.
Cenobamate 200 mg orally once daily initially, titrated weekly by 50 mg to a target dose of 400 mg once daily; maximum 400 mg/day.
None Documented
None Documented
Clinical Note
moderateBrivaracetam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Brivaracetam."
Clinical Note
moderateBrivaracetam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Brivaracetam."
Clinical Note
moderateBrivaracetam + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Brivaracetam."
Clinical Note
moderateBrivaracetam + Fluconazole
Terminal elimination half-life is approximately 9 hours in adults with normal renal function. In patients with severe renal impairment (CrCl <30 mL/min), half-life is prolonged to about 20-30 hours, requiring dose adjustment.
The terminal elimination half-life is approximately 10-17 hours in adults. Steady-state is achieved within 2-3 days. In patients with moderate to severe hepatic impairment, half-life may be prolonged.
Approximately 95% of the dose is excreted renally, with about 8-12% as unchanged drug and the remainder as metabolites (primarily by hydrolysis to the carboxylic acid metabolite). Fecal excretion accounts for less than 1%.
Renal excretion accounts for approximately 92% of the administered dose, with 62% as unchanged drug and 30% as metabolites. Fecal excretion is minimal (<2%).
Category C
Category C
Anticonvulsant
Anticonvulsant
"The metabolism of Fluconazole can be decreased when combined with Brivaracetam."